In this context, the study published by Samaras et al. [98] reveals that p38 MAPK expression had significant association with high Fuhrman’s index in RCC patients, thereby supporting the use of p38 inhibition as a novel therapeutic approach in cancer along with other therapies. The gene discussed is MAPK1; the disease is cancer.